Literature DB >> 23321485

The CC genotype in the T102C HTR2A polymorphism predicts relapse in individuals after alcohol treatment.

Andrzej Jakubczyk1, Anna Klimkiewicz, Maciej Kopera, Aleksandra Krasowska, Małgorzata Wrzosek, Halina Matsumoto, Margit Burmeister, Kirk J Brower, Marcin Wojnar.   

Abstract

The serotonin system is hypothesized to contribute to predisposition and course of alcohol dependence. However, the potential association between the T102C polymorphism (rs6313) in the type 2A serotonin receptor (HTR2A) gene and treatment outcomes in alcohol dependence has not been investigated. The aim of the study was to assess the contribution of this genetic polymorphism as a predictor of relapse in relation to other previously identified predictors. A sample of 254 alcohol dependent subjects, were recruited in alcohol treatment centers in Warsaw, Poland and prospectively assessed at baseline and follow-up after 12 months. At baseline, information about demographics, psychopathological symptoms and alcohol problems was obtained. The stop-signal task was performed and blood samples for genetic analysis of HTR2A T102C (rs6313) were collected. Relapse was defined as any drinking during the follow-up period. The statistical analysis showed that the CC genotype was significantly associated with increased relapse. Other significant factors were baseline depressive symptoms, number of drinking days during the 3 months prior to the baseline assessment, severity of alcohol-related problems, and a lifetime history of impulsive suicide attempts. Logistic regression analysis with and without the genetic factor revealed that adding the genetic factor increased the R square value by about 4%, with the CC genotype in the T102C polymorphism being the strongest predictor of relapse (OR = 2.32). The significant influence on relapse of the CC genotype, which is associated with fewer 5-HT2A receptors in the central nervous system, suggests the possibility that this genetic polymorphism could influence response to serotonergic medications.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23321485      PMCID: PMC3581721          DOI: 10.1016/j.jpsychires.2012.12.004

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  50 in total

1.  The CC genotype in HTR2A T102C polymorphism is associated with behavioral impulsivity in alcohol-dependent patients.

Authors:  Andrzej Jakubczyk; Małgorzata Wrzosek; Jacek Lukaszkiewicz; Joanna Sadowska-Mazuryk; Halina Matsumoto; Elżbieta Sliwerska; Jennifer Glass; Margit Burmeister; Kirk J Brower; Marcin Wojnar
Journal:  J Psychiatr Res       Date:  2011-09-17       Impact factor: 4.791

2.  Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders.

Authors:  Jürgen Rehm; Colin Mathers; Svetlana Popova; Montarat Thavorncharoensap; Yot Teerawattananon; Jayadeep Patra
Journal:  Lancet       Date:  2009-06-27       Impact factor: 79.321

3.  Brain morphology at entry into treatment for alcohol dependence is related to relapse propensity.

Authors:  Valerie A Cardenas; Timothy C Durazzo; Stefan Gazdzinski; Anderson Mon; Colin Studholme; Dieter J Meyerhoff
Journal:  Biol Psychiatry       Date:  2011-05-20       Impact factor: 13.382

4.  A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype.

Authors:  Henry R Kranzler; Stephen Armeli; Howard Tennen; Jonathan Covault; Richard Feinn; Albert J Arias; Helen Pettinati; Cheryl Oncken
Journal:  J Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.153

5.  [Validation of the Polish version of the Athens Insomnia Scale].

Authors:  Małgorzata Fornal-Pawłowska; Dorota Wołyńczyk-Gmaj; Waldemar Szelenberger
Journal:  Psychiatr Pol       Date:  2011 Mar-Apr       Impact factor: 1.657

Review 6.  Contributions of serotonin in addiction vulnerability.

Authors:  L G Kirby; F D Zeeb; C A Winstanley
Journal:  Neuropharmacology       Date:  2011-04-03       Impact factor: 5.250

7.  Epidemiology and alcohol policy in Europe.

Authors:  Jürgen Rehm; Witold Zatonksi; Ben Taylor; Peter Anderson
Journal:  Addiction       Date:  2011-03       Impact factor: 6.526

8.  Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.

Authors:  Bankole A Johnson; Nassima Ait-Daoud; Chamindi Seneviratne; John D Roache; Martin A Javors; Xin-Qun Wang; Lei Liu; J Kim Penberthy; Carlo C DiClemente; Ming D Li
Journal:  Am J Psychiatry       Date:  2011-01-19       Impact factor: 18.112

9.  Association between Val66Met brain-derived neurotrophic factor (BDNF) gene polymorphism and post-treatment relapse in alcohol dependence.

Authors:  Marcin Wojnar; Kirk J Brower; Stephen Strobbe; Mark Ilgen; Halina Matsumoto; Izabela Nowosad; Elzbieta Sliwerska; Margit Burmeister
Journal:  Alcohol Clin Exp Res       Date:  2009-01-27       Impact factor: 3.455

10.  Long-term effects of a personality-targeted intervention to reduce alcohol use in adolescents.

Authors:  Patricia J Conrod; Natalie Castellanos-Ryan; Clare Mackie
Journal:  J Consult Clin Psychol       Date:  2011-06
View more
  5 in total

Review 1.  Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models.

Authors:  Jennifer A Rinker; Patrick J Mulholland
Journal:  Pharmacogenomics       Date:  2017-03-27       Impact factor: 2.533

Review 2.  Alcohol Dependence and Its Relationship With Insomnia and Other Sleep Disorders.

Authors:  Subhajit Chakravorty; Ninad S Chaudhary; Kirk J Brower
Journal:  Alcohol Clin Exp Res       Date:  2016-10-05       Impact factor: 3.455

3.  Hierarchical investigation of genetic influences on response inhibition in healthy young adults.

Authors:  Jessica Weafer; Joshua C Gray; Kyle Hernandez; Abraham A Palmer; James MacKillop; Harriet de Wit
Journal:  Exp Clin Psychopharmacol       Date:  2017-12       Impact factor: 3.157

Review 4.  Neuroscience of inhibition for addiction medicine: from prediction of initiation to prediction of relapse.

Authors:  Scott J Moeller; Lucia Bederson; Nelly Alia-Klein; Rita Z Goldstein
Journal:  Prog Brain Res       Date:  2015-10-21       Impact factor: 2.453

5.  Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).

Authors:  Kenneth Blum; Marlene Oscar-Berman; Zsolt Demetrovics; Debmalya Barh; Mark S Gold
Journal:  Mol Neurobiol       Date:  2014-05-31       Impact factor: 5.590

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.